---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-067651"
form_type: "8-K"
ticker: null
cik: "0001739426"
company_name: "RVL Pharmaceuticals plc"
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:24:52.356335+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RVL Pharma receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq deficiency letter on June 2, 2023 for bid price < $1.00 for 30 consecutive business days.
- Has 180 days, until Nov 29, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
- May qualify for additional 180-day period by transferring to Nasdaq Capital Market if not cured by Nov 29.
- Company may consider a reverse share split to boost share price, subject to board and shareholder approval.
- No immediate impact on listing; delisting possible if not cured within compliance periods.

## SEC filing metadata
- accession: 0001104659-23-067651
- form_type: 8-K
- cik: 0001739426
- company_name: RVL Pharmaceuticals plc
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739426/000110465923067651/0001104659-23-067651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739426/000110465923067651/tm2317701d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-067651
- JSON: https://secwatch.observer/filing/0001104659-23-067651.json
- Plain text: https://secwatch.observer/filing/0001104659-23-067651.txt

## Key facts
- Listing & Compliance Notices
  RVL Pharmaceuticals plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: June 2, 2023, RVL Pharmaceuticals plc (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s ordinary shares, $0.01 nominal value per share (the “Ordinary Shares”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the list
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739426/000110465923067651/0001104659-23-067651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.